Celgene

GNS Healthcare raised $23 million from the venture capital arms of drugmakers and healt | GNS Healthcare has raised $23 million from the venture capital arms of drugmakers and health insurance companies to build out its artificial-intelligence-driven precision medicine platform.

Artificial Intelligence (AI) technology is showing promising growth in the life sciences and healthcare industries. Companies such as Bristol Myers-Squibb have recently announced AI partnerships, and the global AI healthcare market is set to hit $13 billion by 2025.1To ensure that AI reaches its full potential for biopharma, it is essential that our use cases…

Exscientia, an artificial intelligence (AI)-driven drug discovery company, has entered a three-year AI drug discovery partnership with leading biopharma company Celgene, including an initial $25 million upfront payment and eligibility to receive substantial milestones based on the clinical, regulatory and commercial success of the program. In addition, Exscientia is due to receive tiered royalties on…

Dundee University spin-out Exscientia enters a collaboration with a leading US biopharma company.

In a deal with €22M paid upfront and undisclosed “substantial milestones and royalties,” Exscientia will use its artificial intelligence technology to help Celgene speed up the discovery of drug candidates for cancer and autoimmune diseases. “It is the largest AI drug discovery deal done in the industry to date,” said Andrew Hopkins, CEO of…

UK-based Exscientia signed a three-year artificial intelligence (AI)-based drug discovery collaboration with Celgene. As part of the deal, Celgene is paying Exscientia $25 million upfront as well as various undisclosed milestone payments. Exscientia will be eligible for tiered royalties on net sales on any product coming out of the research. Exscientia will use its full-stack…

By Peter Apps, Commentary In October 31 Chinese teenagers reported to the Beijing Institute of Technology, one of the country’s premier military research establishments. Selected from more than 5000 applicants, Chinese authorities hope they will design a new generation of artificial intelligence weapons systems that could range from microscopic robots to computer worms, submarines, drones…

Bristol-Myers Squibb agreed to acquire Celgene Corp. in a record-sized $74 billion deal that will unite two drugmakers battling for advantage in a crowded market for innovative cancer treatments. Both companies have faced investor wariness about their prospects in recent months. Bristol makes an immunotherapy drug called Opdivo that accounts for roughly a quarter of…

For Immediate Release Chicago, IL –August 27, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amazon.com, Inc. AMZN, Microsoft Corporation MSFT, Apple Inc. AAPL,…

Seven deals that brought in nearly $260 million in funding and three acquisitions involving Facebook, Slack and the Bay Club athletic chain top Bay Area venture and private equity news at the end of the week.

Welcome to this week's FiercePharmaAsia report, which includes stories about Celgene's $1.4 billion PD-1 deal with Beigene, Fosun's headache cause | Celgene is buying Chinese firm Beigene’s PD-1 inhibitor BGB-A317, Fosun's stock slides as rumors about its chairman emerge again, Neopharma is making a series of expansions in Japan and Abu Dhabi, and more.

Two high-level biopharma executives are among seven people who face U.S. Securities and Exchange Commission (SEC) charges of racking up $1.7 million in illegal profits and kickbacks through insider trading in advance of 11 announcements that include mergers, a drug approval application, and quarterly earnings of drug and medical technology developers. Celgene’s director of financial…